Concentrations of soluble Fas in maternal serum and amniotic fluid during uncomplicated pregnancies

Journal of the Society for Gynecologic Investigation

Volumn 10, Issue 3, 2003, Pages 158-160

  Malamitsi Puchner, Ariadne ^a   Sarandakou, Angeliki ^a   Papagianni, Vasiliki ^a   Protonotariou, Efthimia ^a   Tziotis, John ^a   Botsis, Dimitrios ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Amniotic fluid; Delivery at term; First and second trimester of pregnancy; Maternal serum; sFas

Indexed keywords

FAS ANTIGEN; FAS LIGAND;

ADULT; AMNION FLUID; APOPTOSIS; ARTICLE; CIGARETTE SMOKING; CONTROLLED STUDY; DELIVERY; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FETUS MEMBRANE; FETUS MONITORING; FIRST TRIMESTER PREGNANCY; GESTATIONAL AGE; HUMAN; IMMUNOLOGICAL TOLERANCE; LABOR; MATERNAL SERUM; NORMAL HUMAN; PARAMETRIC TEST; PREGNANCY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; SECOND TRIMESTER PREGNANCY; STATISTICAL ANALYSIS;

ADULT; AMNIOTIC FLUID; ANTIGENS, CD95; APOPTOSIS; FEMALE; GESTATIONAL AGE; HUMANS; PREGNANCY; REFERENCE VALUES;

EID: 0037390724     PISSN: 10715576     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1071-5576(03)00002-9     Document Type: Article

References (27)

1. Reinhard G., Noll A., Schlebusch H., Malimann P., Ruecker A.V. Shifts in the TH1/TH2 balance during human pregnancy correlate with apoptosis changes. Biochem Biophys Res Commun. 245:1998;933-938.
2. Nagata S., Golstein P. The Fas death factor. Science. 267:1995;1449-1456.
3. Trauth B.C., Klas C., Peters A.M., et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science. 245:1989;301-305.
4. Bellgrau D., Gold D., Selawry H. A role for CD 95 ligand in preventing graft rejection. Nature. 377:1995;630-632.
5. Griffith T., Brunner T., Fletscher S., et al. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science. 270:1995;1189-1192.
6. Hoshimoto K., Hayashi M., Ohkura T. Plasma levels of soluble Fas during normal pregnancy. Gynecol Obstet Invest. 51:2001;96-98.
7. Tanaka M., Suda T., Haze K., et al. Fas ligand in human serum. Nat Med. 2:1996;317-322.
8. Cheng J., Zhou T., Liu C., et al. Protection of Fas-mediated apoptosis by a soluble form of the Fas molecule. Science. 263:1994;1759-1762.
9. Papoff G., Cascino I., Eramo A., Starace G., Lynch D.H., Ruberti G. An N-terminal domain shared by Fas/Apo-1 (CD 95) soluble variants prevents cell death in vitro. J Immunol. 156:1996;4622-4630.
10. Judo S., Kobayashi S., Kayagaki N., et al. Serum levels of soluble Fas/APO-1 (CD 95) and its molecular structure in patients with systemic lupus erythematosus (SLE) and other autoimmune diseases. Clin Exp Immunol. 107:1997;89-95.
11. Hasunuma T., Kayagaki N., Asahara H., et al. Accumulation of soluble Fas in inflamed joints of patients with rheumatoid arthritis. Arthritis Rheum. 40:1997;80-86.
12. Jacobson M.D., Weil M., Raff M.C. Programmed cell death in animal development. Cell. 88:1997;347-354.
13. Narayanan V. Apoptosis in development and disease of the nervous system. 1. Naturally occurring cell death in the developing nervous system. Pediatr Neurol. 16:1997;9-13.
14. Lee D.M., Osathanondh R., Yeh J. Localization of Bcl-2 in the human fetal mullerian tract. Fertil Steril. 70:1998;135-140.
15. Brill A., Torchinski A., Carp H., Toder V. The role of apoptosis in normal and abnormal embryonic development. J Assist Reprod Genet. 16:1999;512-519.
16. Runie R., Lockwood C.J., LaChapelle L., et al. Apoptosis and Fas expression in human fetal membranes. J Clin Endocrinol Metab. 83:1998;660-666.
17. Malamitsi-Puchner A., Sarandakou A., Tziotis J., Trikka P., Creatsas G. Evidence for a suppression of apoptosis in early postnatal life. Acta Obstet Gynaecol Scand. 80:2001;994-997.
18. Lin H., Mosmann T.R., Guilbert L., Tuntipopipat S., Wegmann T.G. Synthesis of T-helper 2-type cytokines at the maternal-fetal interface. J Immunol. 151:1993;4562-4573.
19. Hill J.A., Polgar K., Anderson D.J. T-helper 1-type immunity to trophoblast in women with recurrent spontaneous abortion. JAMA. 273:1995;1933-1936.
20. Clark A.G., Kendall M.D. The thymus in pregnancy The interplay of neural, endocrine and immune influences . Immunol Today. 15:1994;545-551.
21. Medina K.L., Smithson G., Kineade P.W. Suppression of B lymphopoeisis during normal pregnancy. J Exp Med. 178:1993;1507-1515.
22. Athanassakis I., Bleackley R.C., Paetkau V., Guilbert L., Barr P.J., Wegmann T.G. The immunostimulatory effect of T cells and T cell lymphokines on murine fetally derived placental cell. J Immunol. 138:1987;37-44.
23. Smith S.C., Baker P.N., Symonds E.M. Increased placental apoptosis in intrauterine growth restriction. Am J Obstet Gynecol. 177:1997;1395-1401.
24. Moley K.H., Chi M.M., Knudson C.M., Korsmeyer S.J., Mueckler M.M. Hyperglycaemia induces apoptosis in pre-implantation embryos through cell death effector pathways. Nat Med. 4:1998;1421-1424.
25. Forsberg H., Erikson U.J., Welsh N. Apoptosis in embryos of diabetic rats. Pharmacol Toxicol. 83:1998;104-111.
26. Fortunato S.J., Ramkumar M., Bryant C., Lombardi S.J. Programmed cell death (apoptosis) as a possible pathway to metalloproteinase activation and fetal membrane degradation in premature rupture of membranes. Am J Obstet Gynecol. 182:2000;1468-1476.
27. Seishima M., Takemura M., Saito K., et al. Highly sensitive ELISA for soluble Fas in serum. Increased soluble Fas in the elderly. Clin Chem. 42:1996;1911-1914.